Cargando…

Prolonged acidosis is a feature of SGLT2i-induced euglycaemic diabetic ketoacidosis

We describe two cases of SGLT2i-induced euglycaemic diabetic ketoacidosis, which took longer than we anticipated to treat despite initiation of our DKA protocol. Both patients had an unequivocal diagnosis of type 2 diabetes, had poor glycaemic control with a history of metformin intolerance and pres...

Descripción completa

Detalles Bibliográficos
Autores principales: Rafey, Mohammed Faraz, Butt, Arslan, Coffey, Barry, Reddington, Lisa, Devitt, Aiden, Lappin, David, Finucane, Francis M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6765316/
https://www.ncbi.nlm.nih.gov/pubmed/31600728
http://dx.doi.org/10.1530/EDM-19-0087
_version_ 1783454536001650688
author Rafey, Mohammed Faraz
Butt, Arslan
Coffey, Barry
Reddington, Lisa
Devitt, Aiden
Lappin, David
Finucane, Francis M
author_facet Rafey, Mohammed Faraz
Butt, Arslan
Coffey, Barry
Reddington, Lisa
Devitt, Aiden
Lappin, David
Finucane, Francis M
author_sort Rafey, Mohammed Faraz
collection PubMed
description We describe two cases of SGLT2i-induced euglycaemic diabetic ketoacidosis, which took longer than we anticipated to treat despite initiation of our DKA protocol. Both patients had an unequivocal diagnosis of type 2 diabetes, had poor glycaemic control with a history of metformin intolerance and presented with relatively vague symptoms post-operatively. Neither patient had stopped their SGLT2i pre-operatively, but ought to have by current treatment guidelines. LEARNING POINTS: SGLT2i-induced EDKA is a more protracted and prolonged metabolic derangement and takes approximately twice as long to treat as hyperglycaemic ketoacidosis. Surgical patients ought to stop SGLT2i medications routinely pre-operatively and only resume them after they have made a full recovery from the operation. While the mechanistic basis for EDKA remains unclear, our observation of marked ketonuria in both patients suggests that impaired ketone excretion may not be the predominant metabolic lesion in every case. Measurement of insulin, C-Peptide, blood and urine ketones as well as glucagon and renal function at the time of initial presentation with EDKA may help to establish why this problem occurs in specific patients.
format Online
Article
Text
id pubmed-6765316
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Bioscientifica Ltd
record_format MEDLINE/PubMed
spelling pubmed-67653162019-10-02 Prolonged acidosis is a feature of SGLT2i-induced euglycaemic diabetic ketoacidosis Rafey, Mohammed Faraz Butt, Arslan Coffey, Barry Reddington, Lisa Devitt, Aiden Lappin, David Finucane, Francis M Endocrinol Diabetes Metab Case Rep Unusual Effects of Medical Treatment We describe two cases of SGLT2i-induced euglycaemic diabetic ketoacidosis, which took longer than we anticipated to treat despite initiation of our DKA protocol. Both patients had an unequivocal diagnosis of type 2 diabetes, had poor glycaemic control with a history of metformin intolerance and presented with relatively vague symptoms post-operatively. Neither patient had stopped their SGLT2i pre-operatively, but ought to have by current treatment guidelines. LEARNING POINTS: SGLT2i-induced EDKA is a more protracted and prolonged metabolic derangement and takes approximately twice as long to treat as hyperglycaemic ketoacidosis. Surgical patients ought to stop SGLT2i medications routinely pre-operatively and only resume them after they have made a full recovery from the operation. While the mechanistic basis for EDKA remains unclear, our observation of marked ketonuria in both patients suggests that impaired ketone excretion may not be the predominant metabolic lesion in every case. Measurement of insulin, C-Peptide, blood and urine ketones as well as glucagon and renal function at the time of initial presentation with EDKA may help to establish why this problem occurs in specific patients. Bioscientifica Ltd 2019-09-06 /pmc/articles/PMC6765316/ /pubmed/31600728 http://dx.doi.org/10.1530/EDM-19-0087 Text en © 2019 The authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. (http://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Unusual Effects of Medical Treatment
Rafey, Mohammed Faraz
Butt, Arslan
Coffey, Barry
Reddington, Lisa
Devitt, Aiden
Lappin, David
Finucane, Francis M
Prolonged acidosis is a feature of SGLT2i-induced euglycaemic diabetic ketoacidosis
title Prolonged acidosis is a feature of SGLT2i-induced euglycaemic diabetic ketoacidosis
title_full Prolonged acidosis is a feature of SGLT2i-induced euglycaemic diabetic ketoacidosis
title_fullStr Prolonged acidosis is a feature of SGLT2i-induced euglycaemic diabetic ketoacidosis
title_full_unstemmed Prolonged acidosis is a feature of SGLT2i-induced euglycaemic diabetic ketoacidosis
title_short Prolonged acidosis is a feature of SGLT2i-induced euglycaemic diabetic ketoacidosis
title_sort prolonged acidosis is a feature of sglt2i-induced euglycaemic diabetic ketoacidosis
topic Unusual Effects of Medical Treatment
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6765316/
https://www.ncbi.nlm.nih.gov/pubmed/31600728
http://dx.doi.org/10.1530/EDM-19-0087
work_keys_str_mv AT rafeymohammedfaraz prolongedacidosisisafeatureofsglt2iinducedeuglycaemicdiabeticketoacidosis
AT buttarslan prolongedacidosisisafeatureofsglt2iinducedeuglycaemicdiabeticketoacidosis
AT coffeybarry prolongedacidosisisafeatureofsglt2iinducedeuglycaemicdiabeticketoacidosis
AT reddingtonlisa prolongedacidosisisafeatureofsglt2iinducedeuglycaemicdiabeticketoacidosis
AT devittaiden prolongedacidosisisafeatureofsglt2iinducedeuglycaemicdiabeticketoacidosis
AT lappindavid prolongedacidosisisafeatureofsglt2iinducedeuglycaemicdiabeticketoacidosis
AT finucanefrancism prolongedacidosisisafeatureofsglt2iinducedeuglycaemicdiabeticketoacidosis